All enrolled people who gained a minimum of 1 dose of zosuquidar or placebo in the course of induction have been monitored for your occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse activities had been associated with the period of prolonged https://cgs1543524570.targetblogs.com/28577861/a-review-of-paniculoside-i